

Early aggressive use of subcutaneous methotrexate

– financial and health benefits

Innovation Theatre Wednesday 24 April 11.00am



Dr Sandeep Bawa
Consultant Rheumatologist
Gartnavel General Hospital
Glasgow

In this session, Dr Sandeep Bawa will talk about the role subcutaneous methotrexate (SC MTX) can play in significantly cutting the costs of rheumatoid arthritis (RA) treatment. Even though MTX is still widely used as the drug of choice in the treatment of RA, it is recognised that biologics have become increasingly popular¹.

Dr Bawa will then explain how patients at Gartnavel General Hospital can be successfully treated with SC MTX when oral MTX has failed, preventing the need for biologic therapy and potentially saving the NHS hundreds of millions of pounds¹.

Dr Bawa will also mention first line use of SC MTX and show some patient case studies.

This session is free to attend for all registered delegates.

Ref

1. Hassanzadeh R, Mangan C, France J, Bawa S. Subcutaneous methotrexate to cut costs?
The Journal of Rheumatology, 1 August 2012, vol. 39 no. 8, 1764-1765